Cognitive Impairment in early Alzheimer’s Disease
About Alzheimer's Disease
Alzheimer’s Disease is a chronic degenerative condition of the brain affecting more than 50 million people worldwide. It leads to gradual or rapid loss of cognitive ability i.e. the ability to perform tasks, think and remember clearly.
A gradual decline in cognitive function with aging is normal, but in a disease such as Alzheimer’s, the decline may begin earlier and progress faster. In the later stages of disease there are also effects on a person’s ability to function in normal daily life.
Alzheimer’s Disease is characterized by the presence of abnormal protein build-up in the brain, called amyloid plaques and tau neurofibrillary tangles, with associated nerve cell (neuron) degeneration and death, and loss of brain volume. It is not clear why these changes occur or what causes the rapid degeneration and death of the neurons in the brain.
Alzheimer’s Disease develops years before the symptoms of dementia appear. It is likely that brain pathology begins up to 15 years before the appearance of mild cognitive impairment or clinical dementia. Earlier diagnosis and treatment are therefore a vital hurdle to overcome before we see a significant reduction in the burden of this disease. Approximately 8% of those over the age of 65 are affected by mild cognitive impairment (MCI) due to Alzheimer’s Disease, translating to approximately 4.2 million patients in the US alone.
Alzheimer's is a serious public health issue
As the leading cause of death in the UK, and second only to heart disease in Australia, Alzheimer’s Disease is poised to become the next global public health crisis. There are almost 50 million Alzheimer’s Disease sufferers world-wide, and 300,000 in Australia, with the number set to double every 20 years as the population ages.
Worldwide, the aggregate estimated cost of dementia (of which 62% of sufferers are diagnosed with Alzheimer’s Disease) is US$818 billion. Current conservative estimates expect the global cost to double by 2030.
Alzheimer’s Disease is emerging as the most significant health challenge of our time
No cure and limited treatment options currently available
Of the top ten fatal illnesses, Alzheimer’s Disease remains the only one that cannot be prevented, treated or cured.
Recently, the US FDA provisionally approved an antibody therapy that is injected every few weeks for the treatment of Alzheimer’s Disease, based on its ability to reduce amyloid plaques in the brain and a mixed picture of effectiveness in clinical trials. That therapy is required to do more clinical trials to prove its effectiveness and gain a full approval. It is not approved in Australia or the European Union. So far, antibodies to the tau protein have failed in clinical trials. Previously, the early drugs developed to treat Alzheimer’s Disease provided only limited symptomatic benefit without slowing down the underlying disease significantly.
Alzheimer’s Disease sufferers desperately need new treatment options, and ideally, drugs with the potential to reverse the decline in brain function or slow the disease progression.
Association with excess cortisol underpins Xanamem as a potential treatment
While no single clear cause for the development of Alzheimer’s Disease has been identified, there is strong evidence to support an association between excess cortisol – the “stress hormone”- and the development and progression of Alzheimer’s Disease. Increasing age is the single biggest risk factor for developing Alzheimer’s Disease, and more than half of cognitively normal 65 year-olds have been shown to have persistently raised cortisol – it appears that increasing cortisol is a consequence of normal aging.
Actinogen’s drug candidate Xanamem has been specifically designed to target and block production of cortisol inside neurons (cells) in the brain by inhibiting the activity of an enzyme, 11β-HSD1. Blocking this enzyme prevents the conversion of the inactive cortisone into the active cortisol, and thus reduces the effects of cortisol inside cells and on surface receptors outside cells.
The 11β-HSD1 enzyme is highly concentrated in the hippocampus, frontal cortex and cerebellum, the areas of the brain associated with cognitive impairment in neurological diseases, including Alzheimer’s Disease.
ACW focus on early stages of Alzheimer’s Disease
Mild cognitive impairment (MCI) due to Alzheimer’s Disease affects approximately 8% of those over 65 years of age. MCI represents a large unmet need, with a conversion rate to mild-stage Alzheimer’s Disease of approximately 10-15% per annum. Patients with MCI due to Alzheimer’s Disease have the characteristic biomarker evidence of Alzheimer’s Disease brain changes (for example, abnormal β-amyloid levels) as well as subtle problems with memory and thinking. While these changes do not have clear impacts on the day-to-day functioning of patients, they are detectable on sensitive neurophysiologic measures. Xanamem therapy will be tested in both MCI and mild Alzheimer’s Disease stages.
Echouffo-Tcheugui, Justin B., Sarah C. Conner, Jayandra J. Himali, Pauline Maillard, Charles S. DeCarli, Alexa S. Beiser, Ramachandran S. Vasan, and Sudha Seshadri 2018. Neurology: 10-1212.
Robert H. Pietrzak, Simon M. Laws, Yen Ying Lim, Sophie J. Bender, Tenielle Porter, James Doecke, David Ames, Christopher Fowler, Colin L. Masters, Lidija Milicic, Stephanie Rainey-Smith, Victor L. Villemagne, Christopher C. Rowe, Ralph N. Martins, and Paul Maruff, for the Australian Imaging, Biomarkers and Lifestyle Research Group 2017. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 2(1)45-52.
Popp, J., Wolfsgruber, S., Heuser, I., Peters, O., Hull, M., Schroder, J., Moller, H. J., Lewczuk, P., Schneider, A., Jahn, H., Luckhaus, C., Perneczky, R., Frolich, L., Wagner, M., Maier, W., Wiltfang, J., Kornhuber, J., & Jessen, F. 2015. Neurobiology of Aging, 36, 601-607.
Lupien, S. J., de Leon, M., de Santi, S., Convit, A., Tarshish, C., Nair, N. P. V., Thakur, M., McEwen, B. S., Hauger, L., & Meaney, M. J. 1998. Nature Neuroscience, 1(1), 69-73.
Csernansky, J. G., Dong, H., Fagan, A. M., Wang, L., Xiong, C., Holtzman, D. M., & Morris, J. C. 2006. American Journal of Psychiatry, 163, 2164-2169.
Geerlings, M. I., Sigurdsson, S., Eiriksdottir, G., Garcia, M. E., Harris, T. B., Gudnason, V., & Launer, L. J. 2015. Neurology, 85(11), 976-983.
MacLullich, A. M., Deary, I. J., Starr, J. M., Ferguson, K. J., Wardlaw, J. M., & Seckl, J. R. 2005. Psychoneuroendocrinology, 30(5), 505-515.
Lupien, S. J., McEwen, B. S., Gunnar, M. R., & Heim, C. 2009. Nature reviews neuroscience, 10(6), 434-445.
Starkman, M. N., Giordani, B., Gebarski, S. S., Berent, S., Schork, M. A., & Schteingart, D. E. 1999. Biological psychiatry, 46(12), 1595-1602.
Reynolds, R. M., & Webster, S. P. 2015. Neuroendocrinology of Stress, 327-350.
Green K.N., Billings L.M., Roozendaal B. et al. 2006. J. Neurosci. 26: 9047–56.
Lehallier, B., Essioux, L., Gayan, J., Alexandridis, R., Nikolcheva, T., Wyss-Coray, T., & Britschgi, M. 2016. JAMA neurology, 73(2), 203-212.
Ennis, G. E., An, Y., Resnick, S. M., Ferrucci, L., O’brien, R. J., & Moffat, S. D. 2017. Neurology, 88(4), 371-378.
Sapolsky RM, Uno H, Rebert CS et al. 1990. J Neurosci. 10: 2897–2902.
Kimberley E. Stuart, Anna E. King, Carmen M. Fernandez-Martos, Mathew J. Summers & James C. Vickers 2018. Nature Scientific Reports 7: 2764